Table 7.

Treatment endpoints in clinical use

Treatment	Description
Biochemical	Normalization of serum ALT
Virological
HBeAg-positive	Loss of HBeAg, Anti-HBe antibodies, serum HBV-DNA < 2000 IU/mL
HBeAg-negative	Serum HBV-DNA < 2000 IU/mL
Complete	Biochemical and virological response with loss of serum HBsAg
Histological	Decrease in necroinflammatory activity without worsening in fibrosis

ALT: Alanine transaminase; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; HBsAg: Hepatitis B surface antigen.